Palliation of Dyspnea With Mouth Piece Ventilation in AECOPD

Palliation of Dyspnea With Mouth Piece Ventilation in Acute Exacerbation of COPD Without Respiratory Insufficiency

Status

Terminated

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03025425

Enrollment

Registered

2017-01-19

Start date

2017-01-31

Completion date

2020-08-01

Last updated

2021-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD Exacerbation, Dyspnea

Brief summary

An uncontrolled feasibility study on using mouth piece ventilation in palliation of dyspnea in subjects with acute exacerbation of COPD without acute hypercapnic respiratory failure. Subjects are recruited from the local respiratory ward. The main outcomes are the compliance of the subjects with the treatment and alleviation of dyspnea during the treatment period.

Interventions

DEVICETrilogy 100 ® (Philips Respironics)

Mouth piece Ventilation (MPV) using Trilogy 100 ® (Philips Respironics).

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* a previous diagnosis of COPD * hospitalized due to acute exacerbation of COPD * at least moderate dyspnea (NRS = Numeric Rating Scale ≥ 4) * no acute hypoventilation (pH ≥ 7.35 and PCO2 ≤ 6.0 kPa) * able to understand the study and to give informed consent

Exclusion criteria

* unable to participate and use MPV due to e.g. delirium or lack of co-operation * acute hypoventilation (pH \< 7.35 or PCO2 \> 6.0 kPa) * acute need for ventilatory support * the cause of the dyspnea can be successfully treated * unable to give informed consent * a previous chronic hypoxemic or hypercapnic respiratory insufficiency that has been treated on a long-term basis also at home

Design outcomes

Primary

Measure	Time frame	Description
Change in dyspnea after initial period of using MPV	5-60 min	Change in dyspnea after initial period of using MPV

Secondary

Measure	Time frame	Description
Change in dyspnea after 24 hours of using MPV	24 hours	Change in dyspnea after 24 hours of using MPV
Proportion of subjects having side-effects or not being compliant with MPV	24 hours	Proportion of subjects having side-effects or not being compliant with MPV
Proportion of subjects gaining from MPV	24 hours	Proportion of subjects gaining from MPV
Proportion of subjects willing to continue on MPV after the intervention	24 hours	Proportion of subjects willing to continue on MPV after the intervention

Countries

Finland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026